Vanda Pharmaceuticals reports Q EPS (8c) vs. (4c) last year
Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...
Vanda Pharmaceuticals targets $1B revenue by 2030 with expanded psychiatry portfolio
Q4 2024 Management View CEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% ...
Wedbush Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB)
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a ...
The American Journal of Managed Care21h
Oral Roflumilast Shows Promise for Moderate to Severe Psoriasis
Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.